Tag Archives: Skyclary(omaveloxolone)

The first treatment for Australians with a rare neurodegenerative disease could help slow the progression of damage to the nervous system. The Therapeutic Goods Administration approved the use of Skyclary(omaveloxolone) for Australians aged 16 and above with Friedreich’s ataxia (FA) this month. An inherited disease that targets the central nervous system, FA causes walking difficulties, fatigue, slow or slurred speech, and loss of reflexes and sensation in the legs, arms and body. It affects one in every 30,000 people. Continue reading →